Selection of currently ongoing clinical trials evaluating CTLA4 or/and PD1/PD-L1 checkpoint blockade in combination with untargeted and targeted options including other immunotherapeutic approaches for pancreatic cancer as indicated. This evidence concerns the gene CTLA4 and pancreatic neoplasm.